http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CL-2021000216-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
filingDate 2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be4ec29befd009bb6b4747fbf66238c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049d297a74ef7059f05019950d9e2d3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6e0d35eb1742d4c1d274152d14e3605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29511f2954ad04433500d84f68118d9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb1637c419863fdb4c79845f3d54c66b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66f4f883c777ed0e4940d92bc0af6c03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e08af9c64377682a33daab2e1ed082f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9fe1bca5bd07c6058d9c9bd1ee2a368
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca8d6fe709590d8bd0a48928b5fb097
publicationDate 2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CL-2021000216-A1
titleOfInvention 1h-pyrazolo [4,3-d] pyrimidine compounds as toll-like receptor 7 (tlr7) agonists and methods and uses thereof
abstract Compounds according to Formula I are useful as Toll-like receptor 7 (TLR7) agonists. Said compounds can be used in the treatment of cancer, especially in combination with an immunotherapy agent against cancer, or as a vaccine adjuvant.
priorityDate 2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID317468
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA5H2Z9
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21083976
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP58681
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ7KIN0
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID170743
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID493686
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID51284
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCB3Y652
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCBAG55056
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA1XC23
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100534776
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9NYK1
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569845
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCB3Y653

Total number of triples: 44.